176 related articles for article (PubMed ID: 21688743)
1. Impact of automated data collection from urology offices: improving incidence and treatment reporting in urologic cancers.
Penberthy LT; McClish D; Agovino P
J Registry Manag; 2010; 37(4):141-7. PubMed ID: 21688743
[TBL] [Abstract][Full Text] [Related]
2. [RHESOU (Registry in HErault Specialized in Onco-Urology) : the first French Registry specialized in Onco-Urology. One-year experience].
Trouche-Sabatier SG; Rebillard X; Iborra F; Azria D; Daures JP; Poinas G; Abdo N; Delbos O; Gevorgyan A; Marchal S; Guillon R; Millet I; Lamy PJ; Lauche O; Reis-Borges R; Serre I; Topart D; Tretarre B;
Prog Urol; 2020 Dec; 30(16):1038-1044. PubMed ID: 33012630
[TBL] [Abstract][Full Text] [Related]
3. Global Burden of Urologic Cancers, 1990-2013.
Dy GW; Gore JL; Forouzanfar MH; Naghavi M; Fitzmaurice C
Eur Urol; 2017 Mar; 71(3):437-446. PubMed ID: 28029399
[TBL] [Abstract][Full Text] [Related]
4. Urologic cancer in Thailand.
Lojanapiwat B
Jpn J Clin Oncol; 2015 Nov; 45(11):1007-15. PubMed ID: 26355159
[TBL] [Abstract][Full Text] [Related]
5. The value of billing data from oncology practice to supplement treatment information for cancer surveillance.
Penberthy L; Petkov V; McClish D; Peace S; Overton S; Radhakrishnan S; Gillam C
J Registry Manag; 2014; 41(2):57-64. PubMed ID: 25153010
[TBL] [Abstract][Full Text] [Related]
6. Hematologic malignancies: an opportunity to fill a gap in cancer surveillance.
Penberthy L; McClish D; Peace S; Gray L; Martin J; Overton S; Radhakrishnan S; Gillam C; Ginder G
Cancer Causes Control; 2012 Aug; 23(8):1253-64. PubMed ID: 22674222
[TBL] [Abstract][Full Text] [Related]
7. [Primary urological cancers in a context of limited resources: Epidemiology and treatment].
Ouedraogo S; Traore MT; Kambire JL; Ouedraogo S; Bere B; Kabore AF
Bull Cancer; 2019 Oct; 106(10):868-874. PubMed ID: 31350015
[TBL] [Abstract][Full Text] [Related]
8. Increasing occurrence of urological cancers in Slovakia.
Plesko I; Obsitnikova A; Cuninkova M; Tomasek L; Stefanakova D; Kubik A
Neoplasma; 2004; 51(4):248-54. PubMed ID: 15254654
[TBL] [Abstract][Full Text] [Related]
9. Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea.
Joung JY; Lim J; Oh CM; Jung KW; Cho H; Kim SH; Seo HK; Park WS; Chung J; Lee KH; Won YJ
Cancer Res Treat; 2017 Jul; 49(3):607-615. PubMed ID: 27658388
[TBL] [Abstract][Full Text] [Related]
10. Gout patients have an increased risk of developing most cancers, especially urological cancers.
Chen CJ; Yen JH; Chang SJ
Scand J Rheumatol; 2014; 43(5):385-90. PubMed ID: 24825466
[TBL] [Abstract][Full Text] [Related]
11. Bladder, penile, renal pelvis and testis cancers: A population based analysis of incidence and survival 1977-2013.
Tempo J; Logan C; O'Callaghan M; Kahokehr A; Kichenadasse G; D'Onise K; Foreman D
Cancer Epidemiol; 2020 Apr; 65():101692. PubMed ID: 32151978
[TBL] [Abstract][Full Text] [Related]
12. Survey of incidence of urological cancer in South Korea: a 15-year summary.
Cheon J; Kim CS; Lee ES; Hong SJ; Cho YH; Shin EC; Lee WC; Yoon MS
Int J Urol; 2002 Aug; 9(8):445-54. PubMed ID: 12225342
[TBL] [Abstract][Full Text] [Related]
13. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
14. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
15. Double primary cancers of the prostate and bladder: a literature review.
Kinoshita Y; Singh A; Rovito PM; Wang CY; Haas GP
Clin Prostate Cancer; 2004 Sep; 3(2):83-6. PubMed ID: 15479490
[TBL] [Abstract][Full Text] [Related]
16. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.
Joudi FN; Smith BJ; O'Donnell MA; Konety BR
Urology; 2003 Dec; 62(6):1083-8. PubMed ID: 14665360
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune disease and subsequent urological cancer.
Liu X; Ji J; Forsti A; Sundquist K; Sundquist J; Hemminki K
J Urol; 2013 Jun; 189(6):2262-8. PubMed ID: 23228387
[TBL] [Abstract][Full Text] [Related]
18. Incidence of urological cancers in neurological patients: a review of the literature from the EAU Young Academic Urologist Functional Group.
Cancrini F; Osman N; Doizi S; Guillot-Tantay C; Hüsch T; Illiano E; Tutolo M; Tienza A; Culha MG; Vale L; Raison N; Herve F; Grande P; Roupret M; Phé V
Minerva Urol Nephrol; 2023 Apr; 75(2):163-171. PubMed ID: 36999836
[TBL] [Abstract][Full Text] [Related]
19. Trends in cancer of the urinary bladder and urinary tract in elderly in Denmark, 2008-2012.
Jensen TK; Jensen NV; Jørgensen SM; Clark P; Lund L;
Acta Oncol; 2016; 55 Suppl 1():85-90. PubMed ID: 26784363
[TBL] [Abstract][Full Text] [Related]
20. Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practices.
Ellis S; Geana M; Griebling T; McWilliams C; Gills J; Stratton K; Mackay C; Shifter A; Zganjar A; Thrasher B
Trials; 2019 Oct; 20(1):578. PubMed ID: 31590694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
